Susan B. Anthony Pro-Life America says the Trump administration did not give it key commitments on abortion drugs before the White House pulled Heidi Overton's nomination to lead the Food and Drug Administration, Fox News Politics reported Tuesday.
The pro-life group had opposed Overton's confirmation until the administration committed to ending mail-order abortion drugs, according to the outlet. The nomination was withdrawn without those commitments being made.
The standoff puts a spotlight on mifepristone, the first pill in the two-drug medication abortion regimen, and on how the drug reaches women. Mifepristone blocks progesterone, a hormone needed to sustain pregnancy, and is followed by misoprostol to complete the abortion process.
SBA Pro-Life America has pressed Health and Human Services Secretary Robert F. Kennedy Jr. to act. In a Nov. 6 letter, the group called on Kennedy to immediately restore in-person dispensing requirements for mifepristone while the FDA conducts a safety review, Fox News Digital reported.
The group argued that Kennedy has the legal authority to immediately suspend certain drug approvals if he determines they pose an imminent threat to public health, according to Fox News Digital.
Haile McAnally, who serves as communications director for the Nebraska Republican Party and works with SBA Pro-Life America on legislation, told Fox News Digital that she nearly died after taking abortion pills 14 years ago.
"When I took these pills at a clinic and ended up having severe side effects, I wound up alone in my bathtub, almost dying from these pills, needing a blood transfusion at the hospital," McAnally said.
McAnally urged Kennedy and senators to weigh the consequences of easy access to the drugs. "I just continue to urge the federal government, especially RFK Jr. and the senators … to make sure that we really think about the ramifications of letting this go through so easily," she told Fox News Digital. "I think we really need to put women first."
She also warned that shipping the pills directly to women's homes is dangerous. "Mailing them across the country to doorsteps just as easily as you could an Amazon package is not only reckless, it puts a lot of women's lives and safety at risk," she said.
An April 2025 study conducted by the conservative think tank the Ethics and Public Policy Center found that 10.93% of women "experience sepsis, infection, hemorrhaging, or another serious adverse event within 45 days following a mifepristone abortion," according to Fox News Digital.
The fight over Overton's nomination comes as dozens of national and state pro-life organizations urged President Trump to veto any legislation that weakens federal protections for life, as a new pro-abortion Democrat majority prepares to lead Congress next year, LifeNews.com reported.
The organizations asked Trump to publicly declare his intent to veto the Women's Health Protection Act, which would legalize abortions up to birth nationwide, or any appropriations bill that fails to include the Hyde and Weldon amendments and similar pro-life riders, according to LifeNews.com.
The letter described the Women's Health Protection Act as going far beyond the Roe v. Wade era by prohibiting states from protecting women and preborn children before fetal viability, and said it would eliminate mandatory ultrasounds and other safeguards. It also defended the Weldon Amendment's conscience protections, warning that forcing healthcare providers to perform, pay for, cover or refer for abortions would drive more doctors and nurses from the profession.
A Knights of Columbus–Marist Poll from January 2026 found 54% of Americans favor preserving the Hyde Amendment, which has barred most direct taxpayer funding of abortion for 50 years, according to LifeNews.com.
Signatories to that letter include Kristan Hawkins of Students for Life Action, Lila Rose of Live Action, Tierin-Rose Mandelburg of March for Life Action, Quena Gonzalez of the Family Research Council, and leaders from the Christian Medical & Dental Associations, Democrats for Life of America, Liberty Counsel, the Southern Baptist Theological Seminary and dozens of state-based pro-life groups, LifeNews.com reported.
It is not yet known whether the administration will name a new FDA nominee or what commitments, if any, it is willing to make on mifepristone dispensing rules. Kennedy's office has not announced a decision on the Nov. 6 letter.
Our Take
This is what accountability looks like inside a coalition. SBA Pro-Life America did not quietly fall in line behind a nominee because the letter after the nominee's name was an R. It asked for a concrete commitment — end mail-order abortion drugs — and when the administration would not give it, the group said no. That is a pro-life movement that understands the FDA is not a ceremonial post. The agency controls how mifepristone is dispensed, and right now those rules let pills arrive at American doorsteps with fewer safeguards than a shipment of cold medicine.
McAnally's story is not an anecdote to be waved away. Severe bleeding, a blood transfusion, a bathtub — that is what the mail-order model normalizes for women who are told the process is simple and safe. The Ethics and Public Policy Center study putting serious adverse events at nearly 11% deserves a real hearing, not a media blackout.
Trump won in 2024 with the strongest pro-life coalition in a generation behind him. Those voters were promised action, not a nomination fight that ends with the group that helped elect him saying the administration would not commit. The White House should pick a nominee who will restore in-person dispensing, and Kennedy should act on the Nov. 6 letter now. Pro-lifers should be calling the White House and their senators this week and asking one question: what exactly did the administration promise, and why was it not enough to keep the nomination alive?


